David Krizaj retweetledi
Boston biotech has been running the same playbook for years and everyone in the ecosystem knows it.
Early-stage companies are built less on validated biology and more on signaling: a splashy Nature or Science paper, a thin patent scaffold, and the reputational gravity of well-networked academic founders. That combination is often enough to unlock large funding rounds.
The problem is that high-impact publication has become a proxy for truth. It isn’t. It’s a selection mechanism for novelty and narrative.
The result is predictable:
– groupthink gets reinforced
– weak or irreproducible findings persist for years
– dissent is disincentivized
– hype substitutes for validation
In many cases, the goal is not to rigorously test whether an idea is correct, it’s to create enough mystique that it feels important. That perception alone can carry a company surprisingly far.
So it’s not surprising to see the same voices recycled across boards and advisory roles—people who helped build and legitimize this model in the first place.
Flagship Pioneering@FlagshipPioneer
Flagship welcomes @EricTopol M.D., as Academic Advisor. A renowned physician-scientist, researcher, and author, Dr. Topol has long been at the forefront of advancing medicine through science and technology. His leadership at the intersection of digital health, genomics and AI has reshaped how we understand disease detection and prevention. We look forward to working with Dr. Topol as we as we accelerate a new era of preemptive health and medicine.
English
